BR112016029661A2 - retosiban para tratamento de parto prematuro - Google Patents

retosiban para tratamento de parto prematuro

Info

Publication number
BR112016029661A2
BR112016029661A2 BR112016029661A BR112016029661A BR112016029661A2 BR 112016029661 A2 BR112016029661 A2 BR 112016029661A2 BR 112016029661 A BR112016029661 A BR 112016029661A BR 112016029661 A BR112016029661 A BR 112016029661A BR 112016029661 A2 BR112016029661 A2 BR 112016029661A2
Authority
BR
Brazil
Prior art keywords
rectosiban
treatment
premature birth
relates
premature labor
Prior art date
Application number
BR112016029661A
Other languages
English (en)
Inventor
Campbell Sinclair Smith Gordon
Original Assignee
Glaxosmithkline Ip Dev Ltd
The Chancellor Masters And Scholars Of The Univ Of Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, The Chancellor Masters And Scholars Of The Univ Of Cambridge filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112016029661A2 publication Critical patent/BR112016029661A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a um método de tratamento de trabalho de parto prematuro com retosiban em indivíduos com condições que resultam em so-bredistensão uterina incluindo polidrâmnio e gestação múltipla. em outro aspecto, a invenção refere-se a um método para prevenir o trabalho de parto prematuro em in-divíduos pela administração profilática de retosiban.
BR112016029661A 2014-06-16 2014-06-16 retosiban para tratamento de parto prematuro BR112016029661A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/062602 WO2015192878A1 (en) 2014-06-16 2014-06-16 Retosiban for the treatment of pre-term labour

Publications (1)

Publication Number Publication Date
BR112016029661A2 true BR112016029661A2 (pt) 2017-08-22

Family

ID=51014274

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029661A BR112016029661A2 (pt) 2014-06-16 2014-06-16 retosiban para tratamento de parto prematuro

Country Status (10)

Country Link
US (2) US20170119779A1 (pt)
EP (1) EP3154548A1 (pt)
JP (1) JP2017518358A (pt)
KR (1) KR20170029507A (pt)
CN (1) CN106999497A (pt)
AU (2) AU2014397706A1 (pt)
BR (1) BR112016029661A2 (pt)
CA (1) CA2952585A1 (pt)
RU (1) RU2017100906A (pt)
WO (1) WO2015192878A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018013597A2 (pt) 2016-01-04 2019-01-08 ObsEva S.A. composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit
KR20180099708A (ko) * 2016-01-04 2018-09-05 메르크 세로노 에스. 에이. 하이드록시프로필티아졸리딘 카르복사미드 유도체의 알파-아미노 에스테르 및 이의 염 형태, 결정 다형체
US11534428B1 (en) 2018-05-16 2022-12-27 Xoma (Us) Llc Compositions and methods for delaying the incidence of labor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
JP2017518358A (ja) 2017-07-06
RU2017100906A (ru) 2018-07-16
CA2952585A1 (en) 2015-12-23
AU2014397706A1 (en) 2016-12-22
CN106999497A (zh) 2017-08-01
US20170119779A1 (en) 2017-05-04
AU2018204436A1 (en) 2018-07-12
KR20170029507A (ko) 2017-03-15
EP3154548A1 (en) 2017-04-19
US20180161338A1 (en) 2018-06-14
RU2017100906A3 (pt) 2018-07-16
WO2015192878A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112017008284A8 (pt) Bifidobactérias ativadas e métodos para uso das mesmas
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
ECSP16081503A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112016010454A2 (pt) métodos para tratar uma taupatia
DK3230736T3 (da) Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
BR112018007356A2 (pt) métodos de produção de formas fucosiladas e não fucosiladas de uma proteína
BR112015026660B8 (pt) Ligas metálicas aperfeiçoadas para dispositivos médicos
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112016019825A2 (pt) anticorpos do fator bb do complemento
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements